Arteritis: Clinical Trials

6 trials for Arteritis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 6 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Completed 6
Phase 22Completed 2

Follow Arteritis: new trials by email Literature Review of Arteritis trials Research Report on Arteritis

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
Secukinumab - Giant Cell Arteritis, Polymyalgia Rheumatica
Phase 1CompletedNovartis Pharmaceuticals652024-03-272026-04-01
Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers
Tocilizumab Prefilled Syringe - Rheumatoid Arthritis, Giant Cell Arteritis
Phase 1CompletedSyneos Health3002021-05-312024-01-05
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).
Tocilizumab - Giant Cell Arteritis
Phase 1CompletedHoffmann-La Roche242019-08-052021-12-22
Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab
Tocilizumab, Glucocorticoids - Giant Cell Arteritis
Phase 1 / Phase 2CompletedInsel Gruppe AG, University Hospital Bern182018-12-012021-06-22
Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
triamcinolone acetonide (Triesence®) - Uveitis, Intermediate Uveitis
Phase 1 / Phase 2CompletedClearside Biomedical, Inc.112013-02-012021-02-21
MRI Superficial Temporal Artery
MRI - Temporal Arteritis
Phase 1CompletedUniversity Health Network, Toronto52003-04-012007-04-23

Narrower conditions

Giant Cell Arteritis (6)  ·  Arthritis, Rheumatoid (1)  ·  Choroidal Effusions (1)  ·  Inflammation (1)  ·  Ophthalmia, Sympathetic (1)  ·  Panuveitis (1)  ·  Polymyalgia Rheumatica (1)  ·  Uveitis (1)  ·  Uveitis, Intermediate (1)  ·  Uveitis, Posterior (1)

Broader conditions

Autoimmune Diseases (6)  ·  Autoimmune Diseases of the Nervous System (6)  ·  Brain Diseases (6)  ·  Cardiovascular Diseases (6)  ·  Central Nervous System Diseases (6)  ·  Cerebrovascular Disorders (6)  ·  Immune System Diseases (6)  ·  Nervous System Diseases (6)  ·  Skin Diseases (6)  ·  Skin Diseases, Vascular (6)  ·  Skin and Connective Tissue Diseases (6)  ·  Vascular Diseases (6)  ·  Vasculitis (6)  ·  Vasculitis, Central Nervous System (6)

Interventions

tocilizumab (3)  ·  Adrenal Cortex Hormones (1)  ·  Glucocorticoids (1)  ·  Triamcinolone (1)  ·  Triamcinolone Acetonide (1)  ·  secukinumab (1)

Sponsors

Clearside Biomedical, Inc. (1)  ·  Hoffmann-La Roche (1)  ·  Insel Gruppe AG, University Hospital Bern (1)  ·  Novartis Pharmaceuticals (1)  ·  Syneos Health (1)  ·  University Health Network, Toronto (1)

Countries

Switzerland (3)  ·  United States (2)  ·  Australia (1)  ·  Canada (1)  ·  Czechia (1)  ·  India (1)  ·  Italy (1)  ·  New Zealand (1)  ·  Portugal (1)  ·  Spain (1)

Top investigators

Narinder Paul, FRCP C (1)  ·  Peter Villiger, Prof (1)  ·  Thomas Ciulla, MD (1)

Results publications

PMID 27980877, PMID 34117737, PMID 35659282, PMID 37287970, PMID 38287611

NIH funding

2018 (2), 2023 (1)